Emelia J Benjamin Selected Research

N-terminal proatrial natriuretic peptide

1/2010	Relations of biomarkers of distinct pathophysiological pathways and atrial fibrillation incidence in the community.
8/2007	Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring Study.
3/2007	Multiple biomarkers and the risk of incident hypertension.
2/2004	Impact of obesity on plasma natriuretic peptide levels.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Emelia J Benjamin Research Topics

Disease

58	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 03/2003
54	Atrial Fibrillation 08/2022 - 02/2004
49	Inflammation (Inflammations) 01/2020 - 07/2004
47	Hypertension (High Blood Pressure) 01/2021 - 03/2003
44	Heart Failure 08/2022 - 08/2002
25	Myocardial Infarction 03/2022 - 01/2003
23	Stroke (Strokes) 01/2022 - 08/2003
22	Diabetes Mellitus 01/2020 - 12/2004
14	Obesity 03/2022 - 03/2003
14	Coronary Disease (Coronary Heart Disease) 01/2021 - 02/2004
14	Atherosclerosis 01/2021 - 08/2005
10	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2021 - 01/2007
8	Insulin Resistance 05/2017 - 01/2003
6	Neoplasms (Cancer) 03/2022 - 01/2007
6	Chronic Renal Insufficiency 01/2016 - 06/2008
6	Ventricular Remodeling 09/2012 - 03/2003
5	Dementia (Dementias) 01/2022 - 12/2010
5	Hyperemia 10/2018 - 12/2004
5	Thrombosis (Thrombus) 01/2017 - 03/2007
5	Apnea 01/2016 - 10/2006
5	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 11/2013 - 09/2002
4	Sepsis (Septicemia) 11/2021 - 06/2013
4	Albuminuria 09/2021 - 03/2007
4	Fibrosis (Cirrhosis) 01/2021 - 05/2004
4	Ischemic Stroke 01/2017 - 08/2003
4	Type 2 Diabetes Mellitus (MODY) 01/2017 - 02/2006
4	Hypertrophy 11/2013 - 09/2004
3	Cardiac Arrhythmias (Arrythmia) 12/2021 - 06/2014
3	Heart Diseases (Heart Disease) 01/2021 - 08/2007
3	Heart Valve Diseases (Valvular Heart Disease) 01/2020 - 03/2009
3	Atrial Remodeling 01/2020 - 02/2009
3	Coronary Artery Disease (Coronary Atherosclerosis) 09/2017 - 10/2004
3	Alzheimer Disease (Alzheimer's Disease) 01/2017 - 11/2011
3	Infections 04/2015 - 03/2014
3	Necrosis 07/2013 - 06/2008
3	Hypoxia (Hypoxemia) 05/2013 - 05/2008

Drug/Important Bio-Agent (IBA)

63	Biomarkers (Surrogate Marker)IBA 01/2022 - 10/2005
44	C-Reactive ProteinIBA 03/2022 - 03/2003
25	Antihypertensive Agents (Antihypertensives)IBA 03/2022 - 04/2003
23	HDL CholesterolIBA 01/2021 - 03/2003
23	Interleukin-6 (Interleukin 6)IBA 01/2017 - 03/2003
15	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 01/2003
15	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 01/2021 - 12/2004
14	Fibrinogen (Factor I)FDA Link 01/2018 - 03/2007
14	Brain Natriuretic Peptide (Natrecor)FDA Link 10/2014 - 09/2002
13	CreatinineIBA 09/2021 - 03/2003
13	CholesterolIBA 01/2021 - 12/2004
13	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 02/2015 - 07/2004
12	Natriuretic PeptidesIBA 01/2018 - 08/2002
12	LipidsIBA 01/2017 - 11/2006
11	Biological ProductsIBA 09/2016 - 02/2006
11	AldosteroneIBA 01/2010 - 05/2004
10	AlbuminsIBA 09/2021 - 02/2006
10	P-SelectinIBA 01/2018 - 04/2006
9	OsteoprotegerinIBA 02/2016 - 06/2008
9	ReninIBA 01/2010 - 02/2006
8	HomocysteineIBA 01/2017 - 03/2004
7	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2017 - 03/2003
6	Proteins (Proteins, Gene)FDA Link 01/2020 - 06/2006
6	Plasminogen Activator Inhibitor 1IBA 01/2018 - 02/2006
6	AdipokinesIBA 05/2017 - 03/2009
6	Atrial Natriuretic Factor (ANF)IBA 03/2016 - 02/2004
6	CD40 Ligand (CD40L)IBA 02/2015 - 01/2008
6	Triglycerides (Triacylglycerol)IBA 12/2014 - 02/2006
5	Warfarin (Coumadin)FDA LinkGeneric 01/2022 - 08/2003
5	MicroRNAs (MicroRNA)IBA 01/2020 - 04/2014
5	Vasodilator Agents (Vasodilators)IBA 05/2017 - 12/2004
5	Type II Tumor Necrosis Factor ReceptorsIBA 09/2016 - 03/2011
5	Lipoproteins (Lipoprotein)IBA 02/2016 - 11/2005
5	Oxyhemoglobins (Oxyhemoglobin)IBA 01/2016 - 10/2006
5	1-Alkyl-2-acetylglycerophosphocholine Esterase (PAF Acetylhydrolase)IBA 02/2015 - 06/2009
4	Indicators and Reagents (Reagents)IBA 08/2022 - 02/2008
4	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2019 - 10/2004
4	LeptinIBA 01/2018 - 04/2009
4	CalciumIBA 11/2017 - 02/2004
4	Pharmaceutical PreparationsIBA 06/2017 - 09/2007
4	IsoprostanesIBA 02/2016 - 02/2008
4	AdiponectinIBA 02/2016 - 03/2009
4	Peroxidase (Myeloperoxidase)IBA 02/2015 - 03/2011
4	Tissue Inhibitor of Metalloproteinase-1IBA 12/2010 - 09/2004
4	Peptides (Polypeptides)IBA 08/2010 - 02/2004
4	N-terminal proatrial natriuretic peptideIBA 01/2010 - 02/2004
4	SodiumIBA 03/2008 - 02/2004
3	Blood Glucose (Blood Sugar)IBA 01/2022 - 03/2003
3	AnticoagulantsIBA 11/2021 - 08/2015
3	Vitamin K FDA Link 01/2020 - 02/2008
3	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 01/2018 - 03/2011
3	P-2 (P 2)IBA 01/2018 - 03/2009
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 09/2016 - 05/2009
3	Troponin IIBA 05/2016 - 01/2014
3	Arginine (L-Arginine)FDA Link 01/2016 - 03/2009
3	N,N-dimethylarginine (asymmetric dimethylarginine)IBA 01/2016 - 03/2009
3	HDL LipoproteinsIBA 01/2016 - 01/2005
3	LigandsIBA 03/2014 - 11/2008
3	ResistinIBA 09/2012 - 03/2009
3	VitaminsIBA 07/2012 - 09/2007

Therapy/Procedure

18	Therapeutics 11/2021 - 02/2006
7	Catheter Ablation 11/2020 - 02/2010
6	Hormone Replacement Therapy (Therapy, Hormone Replacement) 01/2016 - 05/2005
4	Secondary Prevention 01/2021 - 02/2009